GlassScriptPhysician profile
Mukeshkumar Devshibhai Delvadiya
NPI 1003070004
$7,826.94
in general payments reported to CMS, 2019-2025
57 companies · $2,358 in 2025
The $2,358 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $248 · 2021: $133 · 2022: $1,114 · 2023: $1,430 · 2024: $2,309 · 2025: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,788 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,787.87 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $112.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,670.25 | 2020-2025 | |
| Celgene Corporation | $511.10 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $510.42 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Incyte Corporation | $412.99 | 2019-2025 | Monjuvi |
| Pfizer INC. | $326.38 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $291.45 | 2019-2025 | Opdivo, Reblozyl |
| Genzyme Corporation | $279.18 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $276.06 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $252.86 | 2020-2025 | Lynparza, Enhertu |
| Eisai INC. | $220.29 | 2022-2025 | |
| Sobi, INC | $196.14 | 2022-2025 | |
| Glaxosmithkline, LLC. | $188.66 | 2022-2025 | Shingrix, Ojjaara, Blenrep |
| Gilead Sciences, INC. | $176.70 | 2022-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $158.39 | 2019-2024 | Tavalisse, Rezlidhia |
| Amgen INC. | $150.53 | 2021-2023 | Lumakras |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $140.06 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $133.53 | 2022-2025 | Xpovio |
| Pharmaessentia USA Corporation | $128.57 | 2022-2025 | Besremi |
| Daiichi Sankyo INC. | $117.37 | 2019-2025 | Enhertu, Injectafer |
| Abbvie INC. | $114.94 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.23 | 2023-2025 | Fruzaqla, Vonvendi, Iclusig |
| Epizyme, INC. | $99.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.39 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $78.18 | 2023-2025 | Clonoseq |
| Astellas Pharma US INC | $76.91 | 2023-2024 | Xtandi, Padcev |
| Array Biopharma INC | $75.72 | 2023-2025 | Lorbrena, Mektovi, Xalkori |
| Seagen INC. | $74.34 | 2022-2023 | Adcetris, Tukysa |
| Pharmacosmos Therapeutics INC. | $66.98 | 2024-2025 | Monoferric |
| Genentech USA, INC. | $61.68 | 2019-2022 | |
| Stemline Therapeutics INC. | $57.83 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $56.74 | 2024 | Brukinsa |
| Ge Healthcare | $54.26 | 2022 | |
| Aveo Pharmaceuticals, INC. | $50.17 | 2023-2025 | Fotivda |
| Adc Therapeutics America, INC. | $48.94 | 2023-2025 | |
| Blueprint Medicines Corporation | $46.79 | 2023-2025 | Ayvakit |
| Puma Biotechnology, INC. | $40.16 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $37.21 | 2023 | Imbruvica, Epkinly |
| Myriad Genetic Laboratories, INC. | $35.17 | 2022-2023 | Precisetumor |
| Alnylam Pharmaceuticals INC. | $32.81 | 2024-2025 | Givlaari |
| Janssen Scientific Affairs, LLC | $30.64 | 2022 | |
| Taiho Oncology, INC. | $28.52 | 2022 | |
| Kite Pharma, INC. | $27.72 | 2023 | |
| Tempus Ai, INC | $26.12 | 2024 | Xt Cdx |
| Sirtex Medical INC | $25.36 | 2023 | Sir-Spheres Microspheres |
| Cti Biopharma Corp. | $24.42 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $23.59 | 2023 | Libtayo |
| Springworks Therapeutics, INC. | $23.41 | 2024 | Ogsiveo |
| Emd Serono, INC. | $21.24 | 2023 | Bavencio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.83 | 2025 | |
| Agios Pharmaceuticals, INC. | $20.23 | 2025 | Pyrukynd |
| Ipsen Biopharmaceuticals, INC | $19.78 | 2022 | |
| Verastem, INC. | $18.40 | 2019 | |
| Tersera Therapeutics LLC | $16.92 | 2025 | Zoladex |
| Exelixis INC. | $16.63 | 2025 | Cabometyx |
| Foundation Medicine, INC. | $16.40 | 2023 | |
| Lilly USA, LLC | $14.31 | 2023 | Jaypirca, Retevmo, Verzenio |
| Mylan Institutional INC. | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukeshkumar Delvadiya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.